Ibex™ Solutions consist of three innovative CDMO offerings that span the complete product lifecycle of a biopharmaceutical – from preclinical to commercial stages, from drug substance to drug product, all in one location.
The three offerings Ibex™ Design, Ibex™ Develop, and Ibex™ Dedicate have been developed as a response to a dynamic market and evolving needs. To help you take your drug candidate to market quickly. To give you flexibility to manage the unknown. To streamline your supply. To increase predictability.
The home for Ibex™ Solutions is the Lonza biopark in Visp (CH), which leverages Lonza's existing infrastructure, support networks and a stable and highly skilled workforce.
Product lifecycle management at a single site, from the very beginning
Ibex™ Design is our offering for your preclinical and IND needs through to clinical phase I. It includes a pioneering fixed price gene-to-vial package, with delivery of drug product within 12 months and at least 1 kg drug substance. To further increase predictability for you, we offer a manufacturing slot reserved for your clinical resupply. Benefit from our proven GS Gene Expression System® bioprocess platform and a holistic development strategy with the endpoint in mind.
Seamless transition from clinical to commercial manufacturing
Accelerate your market readiness with Ibex™ Develop. From the start of process characterization, we can help you to achieve your BLA submission in just 22 months. Clinical and commercial production are under the same roof, which simplifies comparability requirements and eliminates the need for tech transfers between sites. Our regulatory experience, illustrated by seven fast track BLA submissions we helped prepare in 2012-17, could help you to de-risk your filing.
A fully customized commercial supply solution, exclusive for your product or portfolio
Our innovative, high-responsive supply solution Ibex™ Dedicate allows you to delay your capacity build decisions and better manage investment risk. A pre-built wing and faster ramp-up save you up to 30 months total time to market. Flexible ownership and operating models give you freedom of choice, in combination with a technology-agnostic solution that can be tailored to suit mammalian and microbial production, vaccines, and cell and gene therapy.
Are you looking for a reliable, experienced, and agile partner to help you take your next drug to the market faster? Are you interested in exploring game changing business and operating models for your pre-clinical, clinical and commercial needs? Let’s meet your next milestone together.